Warfarin in primary care

Slides:



Advertisements
Similar presentations
Atrial Fibrillation Service
Advertisements

ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.
Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.
Warfarin toxicity Presented by: Dr.Somaia Janah Presented by: Dr.Somaia Janah.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Prophylaxis of Venous Thromboembolism
Medications that impact bleeding By Nino Lalaiants Inesa Legrian NYCCT 2012.
MTP Octaplex rFVIIa Calgary. Massive Transfusion Protocol.
Bleeding time,clotting time, PT, and PTT
DR. HANA OMER CONGENITAL HEART DEFECTS. The major development of the fetal heart occurs between the fourth and seventh weeks of gestation, and most congenital.
Hemostasis and Blood Coagulation
ANTICOAGULANT BY :DR ISRAA OMAR.
Angiography Excessive Commercialisation Complications of Angiography 1.Death 2.Myocardial Infarction Factors predisposing Unstable angina Angina at rest.
WARFARIN AN OVERVIEW.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
Study Guide Guide for Patients Undergoing Anticoagulant Therapy.
Secondary prevention after a TIA or ischemic stroke.
Thromboprophylaxis in Pregnancy and the Puerperium
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.
Pulmonary Embolism Pulmonary embolism is blockage in one or more arteries in your lungs. Maggie Trainor.
Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
MEDICAL HISTORY. WHY TAKE A MEDICAL HISTORY? Individuals are surviving what used to be fatal diseases and have more chronic conditions Dental treatment.
CONGENITAL HEART DEFECTS DR. HANA OMER. CONGENITAL HEART DEFECTS D. HANA OMER.
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
Low risk: young, with minor illnesses, who are to undergo operations lasting 30 min or less. Moderate risk: over 40 or with a debilitating illness who.
ANTIPHOSPHOLIPID SYNDROME CLINICAL MANIFESTATIONS.
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Warfarin PSD/HOF001/GB/DC/Rev013 Issued : Review interval:12 months This document may be reviewed and reissued electronically without notice.
Anticoagulants Course: Pharmacology I Course Code: PHR 213 Course Instructor: Sabiha Chowdhury Lecturer Department of Pharmacy BRAC University.
Course Lecturer: Imon Rahman
Unit 7: Circulatory System 4b. Analyze, and explain the relationships between the respiratory and cardiovascular systems as they obtain oxygen needed for.
Anticoagulant Therapy
R4 문정락 / IC prof. 김진배 Lancet Haematol 2015;2: e150–59.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D.,
Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.
STAFFORDSHIRE THROMBOSIS AND ANTICOAGULATION CENTRE (STAC) PATIENT SPECIFIC DIRECTION FOR DALTEPARIN (LMWH) FOR PATIENTS WITH VENOUS THROMBO-EMBOLISM (VTE)/MECHANICAL.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Date of download: 6/26/2016 From: Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Sex Differences in Hospital Mortality in Adults With.
Dep. Of Hemato-Oncology R1. Choi In-Ah D-dimer Testing to Determine the Duration of Anticoagulation Therapy Gualtiero Palareti,M.D., Benilde Cosmi, M.D.,
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
Atrial fibrillation J Heinsimer MD.
Ahmed Mohamed Abd Elmajeed 99
Bleeding disorders Deficiency of any of the clotting factors leads to excessive bleeding Most common and important bleeding disorders are due Vitamin K.
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Prothrombin complex concentrate
Copyright © 2012 American Medical Association. All rights reserved.
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
Cariovascular pharmacology for primary care physician: cardiotonics, antiarrhytmics, vasodilatators Domina Petric, MD.
Ortho Warfarin Dosing Protocol
Medications for the respiratory system
Domina Petric, MD Hypolipidemic drugs.
The normal haemostasis process involves three stages: 1
Oral antidiabetic drugs (for primary care physician)
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Atrial fibrillation (AF) and flutter
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Intra vascular anti-coagulants
Owen N. Johnson, MD, David L
Venous Thromboembolism with Chronic Liver Disease
Pradaxa Jeopardy Copyright 2001.
New-Onset Postoperative Atrial Fibrillation and Long-Term Survival After Aortic Valve Replacement Surgery  Giovanni Filardo, PhD, MPH, Cody Hamilton,
Efficacy and safety outcomes with NOAC compared with warfarin in NOAC patients with 14 457 years of risk and 49 418 warfarin patients with 75 747.
ACC 2003 Late Breaking Trials
Presentation transcript:

Warfarin in primary care Domina Petric, MD

Indications Warfarin tbl. 3 mg or 5 mg treatment and prevention of deep venous thrombosis and pulmonary embolism secondary prevention of myocardial infarction and prevention of thromboembolic complications (cerebrovascular insult, systemic embolism) after myocardial infarction prevention of thromboembolic complications in patients with atrial fibrillation, heart valve diseases or artificial heart valves

Dose (adults) Treatment goal are INR values 2,5-3,5 (patients with arteficial heart valves) or INR values 2,0-3,0 (for other indications). Patients with normal body weigh and initial INR value 1,2: 10 mg of warfarin (two tablets of 5 mg or three and one third of 3 mg tablets) during first three days. INR is measured the fourth day and then the dose should be titrated. If the INR value is too low, the dose should be increased. If the INR value is good, the dose should be the same. If the INR value is too high, the dose should be lowered (or one day without a single tablet).

If there is risk of bleeding Patients without signs of bleeding: INR Treatment 4-5 One day without a single tablet, next day a lower dose, control after 7 days. 5-9 Stop one day (one day without a single tablet) and K vitamin 2-3 mg per os, control tomorrow. >9 Stop one day the treatment and K vitamin 5 mg per os, control tomorrow.

If there is bleeding INR Treatment Smaller bleeding Patients with signs of bleeding: INR Treatment Smaller bleeding What is the cause of bleeding? Lower the dose and vitamin K per os if necessary. Larger bleeding Hospitalisation! Life threatening bleeding Emergent hospitalisation!

Elective surgical procedures Seven days before elective surgery check your patient´s INR value! INR When to stop treatment? >4 Stop the treatment five days before surgery. 3-4 Stop the treatment three days before surgery. 2-3 Stop the treatment two days before surgery.

Contraindications Listed below: first trimester and last four weeks of pregnancy von Willebrand disease, hemophilia, thrombocytopenia, damaged thrombocyte function severe liver failure or cirrhosis poorly controled arterial hypertension recent intracranial bleeding surgical procedure on the brain or on the eye gastrointestinal bleeding infective endocarditis, pericardial effusion dementia, psychosis, alcoholism hypersensitivity Hypericum perforatum

MEDIATELY HALMED Warfarin should never be combined with NSAR!!! Literature MEDIATELY HALMED